Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients
Anna S. Berghoff(Medical University of Vienna), Peter Birner(Medical University of Vienna), M. Rudas(Comprehensive Cancer Center Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Guenther G. Steger(Mount Vernon Hospital), Zsuzsanna Bagó-Horváth(Comprehensive Cancer Center Vienna), Matthias Preusser(Medical University of Vienna), Gerda Ricken(Medical University of Vienna), Peter Dubsky(Hirslanden Klinik St. Anna), Christoph Zielinski(Vienna General Hospital), Berthold Streubel(Medical University of Vienna), Rupert Bartsch(Universitätszahnklinik Wien), Florian Fitzal
Cited by 69
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Breast cancer
|The Lancet|2016|2.3k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k